Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Short-term Investments: 2010-2024

Historic Short-term Investments for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Dec 2024 value amounting to $826.2 million.

  • Madrigal Pharmaceuticals' Short-term Investments rose 6.28% to $814.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $814.1 million, marking a year-over-year increase of 6.28%. This contributed to the annual value of $826.2 million for FY2024, which is 54.66% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Short-term Investments of $826.2 million as of FY2024, which was up 54.66% from $534.2 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Short-term Investments peaked at $826.2 million during FY2024, and registered a low of $27.2 million during FY2022.
  • Moreover, its 3-year median value for Short-term Investments was $534.2 million (2023), whereas its average is $462.6 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 88.37% in 2022, then spiked by 1,862.23% in 2023.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Short-term Investments stood at $230.1 million in 2020, then rose by 1.71% to $234.1 million in 2021, then plummeted by 88.37% to $27.2 million in 2022, then spiked by 1,862.23% to $534.2 million in 2023, then soared by 54.66% to $826.2 million in 2024.